Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

In this study, a meta-analysis of randomized controlled trials comparing ursodeoxycholic acid (UDCA) monotherapy with combination therapies utilizing UDCA and budesonide was performed. We found that combination therapy with UDCA and budesonide was more effective than UDCA monotherapy for primary bil...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huawei, Yang, Jing, Zhu, Rong, Zheng, Yuanyuan, Zhou, Yuqing, Dai, Weiqi, Wang, Fan, Chen, Kan, Li, Jingjing, Wang, Chengfen, Li, Sainan, Liu, Tong, Abudumijiti, Huerxidan, Zhou, Zheng, Wang, Jianrong, Lu, Wenxia, Wang, Junshan, Xia, Yujing, Zhou, Yingqun, Lu, Jie, Guo, Chuanyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304592/
https://www.ncbi.nlm.nih.gov/pubmed/25632224
http://dx.doi.org/10.2147/DDDT.S74515
Descripción
Sumario:In this study, a meta-analysis of randomized controlled trials comparing ursodeoxycholic acid (UDCA) monotherapy with combination therapies utilizing UDCA and budesonide was performed. We found that combination therapy with UDCA and budesonide was more effective than UDCA monotherapy for primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. Moreover, compared to prednisone, budesonide has fewer side effects.

Ejemplares similares